~~<i id='36A338827F'><strike id='36A338827F'><tt id='36A338827F'><pre id='36A338827F'></pre></tt></strike></i>~~

00:00

00:00 00:00 LIVE

buffering

Replay

hotspot

leisure time

author：entertainment 2025-09-27 09:46:24 - browse：77591

The Food and Drug Administration on Thursday approved a gene therapy to treat people with hemophilia A, an inherited and rare bleeding disorder.

The treatment, called Roctavian, is made by BioMarin Pharmaceutical. It was first approved in Europe in August 2022.

Roctavian is a one-time therapy that, in clinical trials, dramatically reduced bleeding episodes and helped patients live without the blood transfusions used to treat the disease. The FDA first rejected Roctavian in 2020, asking BioMarin to amass more data on its safety and long-term durability, and then delayed its decision again to account for additional evidence.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： United colonoscopy coverage change 'may cost lives,' doctors say
Next article： Medical device trials still don't enroll enough women, study finds

leisure time

Wikipedia

explore

hotspot

knowledge

explore

AdobeU.S.News&WorldReport recentlyissuedits2023-24BestHospitalsratings.Theratingscomeatatimeofin

WSS

'Essentially witchcraft:' A former naturopath takes on the field

Study finds new variant for Parkinson’s in African populations

Appeals court upholds limits to abortion pill

Why more medical students aren't specializing in primary care

FDA panel gives mixed vote on blood pressure devices

Cheap, fast test for Zika and dengue could cost just $1

hotspot

leisure time

leisure time

FDA approval of Sarepta Duchenne genetic therapy gives me hope

The system is set up to fail children with medical complexity

The high cost of giving birth even with insurance

Drug firms test therapies to halt Alzheimer’s before symptoms arise

New air purifier tech could be key to improving indoor air quality

Teladoc has a new CEO, but challenges remain the same

Apple is now the first public company to be valued at $3 trillion

Cigna wins case to block Amy Bricker's move to CVS

At least 13 dead in Texas as scorching temps continue

Cheap, fast test for Zika and dengue could cost just $1

Wikipedia

Readers discuss the intersection of pregnancy and addiction

CDC advisory panel says seniors 'may' get RSV vaccine

Stephen Quake on the Chan Zuckerberg quest to conquer disease

Cancer thrives by mutating. But sometimes, a mutation leaves it vulnerable

New report analyzes digital physical therapy solutions' effectiveness

NYU Langone launches private ChatGPT for its health care data

explore

hotspot

knowledge

explore